TENAX THERAPEUTICS, INC. (TENX) AI Stock Summary

Snapshot

Tenax Therapeutics is a development-stage biotech with no revenue and a significant cash burn. The company reported a FY 2025 net loss of $52.6M but holds $118M in cash following warrant exercises, extending its operational runway into the second quarter of 2028. The share count ballooned by 157% over the past year due to dilution. While the balance sheet is currently healthy with zero debt, the business relies entirely on clinical success, which recently suffered a major setback.

What's Happening Right Now

• Mon 10th Aug '26 · Clinical Trial: Tenax announced that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary endpoint and a key secondary endpoint, though exploratory analyses showed some positive biomarker trends.
• Fri 31st Jul '26 · Earnings: Tenax reported $118M in cash with a runway extending into Q2 2028, bolstered by warrant proceeds, while R&D expenses increased to $12.9M for the quarter.
• Tue 30th Jun '26 · Supply Deal: Tenax signed a supply agreement with Orion Corporation to manufacture orally administered levosimendan, extending the regulatory approval deadline to 2035.

Ownership

Institutions hold 54.4% and insiders hold 0.1%.

Bottom Line

Tenax is a high-risk, binary bet on a heart drug that just failed its primary Phase 3 trial. The company has a comfortable cash cushion to survive for another two years, but without a successful product, that money is essentially a countdown clock. Investors need to believe management can pivot the trial design or find a new path with the FDA to justify holding the stock.